Cart
sales@molnova.com
Aranidipine
CAS No. 86780-90-7
Aranidipine( MPC1304 )
Catalog No. M20129 CAS No. 86780-90-7
Aranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 36 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 110 | In Stock |
|
| 100MG | 166 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAranidipine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.
-
DescriptionAranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.(In Vivo):Aranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.
-
In Vitro——
-
In VivoAranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.
-
SynonymsMPC1304
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel
-
Research AreaCardiovascular Disease
-
IndicationAngina pectoris and high blood pressure
Chemical Information
-
CAS Number86780-90-7
-
Formula Weight388.37
-
Molecular FormulaC19H20N2O7
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)=O
-
Chemical Name(+-)-Acetonyl methyl 14-dihydro-26-dimethyl-4-(o-nitrophenyl)-35-pyridinedicarboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Masumiya H et al. Inhibition of T-type and L-type Ca(2+) currents by aranidipine a novel dihydropyridine Ca(2+) antagonist. Pharmacology. 2000 Aug;61(2):57-61.
molnova catalog
related products
-
Ethosuximide
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
-
(S)-crizotinib
(S)-crizotinib（IC50 of 72 nM）, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.
-
Sipatrigine
Sipatrigine (619C89) is an antiepileptic compound with neuroprotective activity through glutamate release, TREK ion channels, TRESK channels, sodium channels, and calcium channel inhibitors in the CNS, and can be used to study TRESK channels.
